Medical Developments (ASX:MVP) share price hits new 52 week low

The Medical Developments share price is continuing to struggle today.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Medical Developments International Ltd (ASX: MVP) share price has fallen to a new 52-week low today.

The company hasn't released any news for nearly a fortnight. However, the last time the market heard from Medical Developments, it shared dire news.

Right now, the Medical Developments share price is $3.25, 2.99% lower than its previous close. It marks a new 12-month record low.

Additionally, Medical Developments was dropped from the S&P/ASX 300 Index (ASX: XKO) on Monday night.

Let's take a closer look at the latest from the specialised healthcare company.

laboratory workers looking disappointed

Image source: Getty Images

Medical Developments struggles on the ASX

The last 2 weeks have been tough for the Medical Developments share price.

First off, the company released its earnings for financial year 2021 (FY21), sending its stock plummeting.

Medical Developments reported it had ended FY21 with a $12.6 million loss. For comparison, it reported a net profit after tax of $379,000 for FY20.

However, the company's revenue increased by 12.1% to 25.6 million in FY21.

Medical Developments also provided a promising outlook for FY22, stating it's looking forward to seeing strong sales growth for the year ending 30 June 2022.

Since the company released its FY21 results, Medical Development's shares have fallen 18.6%.

More recently, the company was dropped from S&P Dow Jones Indices' S&P/ASX 300 Index after Monday's close.

Following the company's removal from the index, Medical Developments' stock fell by 3% on Tuesday.

Medical Developments share price snapshot

Today's fall included, the Medical Developments share price has dropped more than half its value in 2021.

It is currently 51% lower than it was at the start of this year. It is also 41% lower than it was this time last year.

The company has a market capitalisation of around $233 million.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Medical Developments International Limited. The Motley Fool Australia owns shares of and has recommended Medical Developments International Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A group of people in a corporate setting do a collective high five.
Healthcare Shares

ASX 300 healthcare stock outperforming today on 'strategic' leadership news

The ASX healthcare stock announced the outcome of its CEO recruitment drive this morning.

Read more »

Cropped shot of a young female scientist working on her computer in the laboratory.
Healthcare Shares

Could Telix shares be a millionaire-maker stock?

Telix looks a compelling growth story, with brokers eyeing more than 150% upside.

Read more »

A child covering his eyes hiding from a toy bear.
Healthcare Shares

Down 20% in 2026, is now the time to buy CSL shares?

CSL shares hit a new multi-year low as the 2026 decline deepens.

Read more »

Scientists in white coats look disappointed.
Healthcare Shares

Down 87% since Thursday, why is this ASX 300 healthcare stock sliding again today?

The ASX healthcare share has plunged more than 87% in five trading days.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Which ASX biotech's shares have jumped more than 10% on positive clinical trial news?

A potential cancer treatment is progressing.

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

3 ASX healthcare stocks tipped to soar over 100% higher this year

These ASX shares are on my radar this week.

Read more »

Scientists working in the laboratory and examining results.
Opinions

3 reasons to buy CSL shares today

The ASX biotech company has great growth potential this year.

Read more »

a man lies on his back on grass with his eyes shut and a contented look on his face as though he is dreaming
Broker Notes

With global populations ageing, are ResMed shares a good buy today?

A leading expert delivers his verdict on the outlook for ResMed shares.

Read more »